| Company Name: |
amyjet
|
| Tel: |
4006800868;027-59626688 18371453821;18771149750 |
| Email: |
sales@amyjet.com |
| Products Intro: |
Product Name:Bicyclo Prostaglandin E2
Package:1EA/
|
| Company Name: |
Cayman Chemical Company
|
| Tel: |
800-364-9897 |
| Email: |
sales@caymanchem.com |
| Products Intro: |
Product Name:Bicyclo Prostaglandin E2
|
| Company Name: |
Neobioscience Co., Ltd.
|
| Tel: |
4006-800-892 |
| Email: |
info@neobioscience.com |
| Products Intro: |
Product Name:Bicyclo Prostaglandin E2
|
|
| | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2 Basic information |
| Product Name: | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2 | | Synonyms: | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2;BICYCLO PROSTAGLANDIN E2;CGCZPIJMGKLVTQ-PAJBVNRRSA-N;(Z)-7-[(2,5-Dioxo-4-butyloctahydro-1H-inden)-1-yl]-5-heptenoic acid;5-Heptenoic acid, 7-[(1R,3aS,7aS)-4-butyloctahydro-2,5-dioxo-1H-inden-1-yl]-, (5Z)- | | CAS: | 109826-53-1 | | MF: | C20H30O4 | | MW: | 334.45 | | EINECS: | | | Product Categories: | | | Mol File: | 109826-53-1.mol |  |
| | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2 Chemical Properties |
| Boiling point | 510.3±35.0 °C(Predicted) | | density | 1.069±0.06 g/cm3(Predicted) | | solubility | DMF: >25 mg/ml
DMSO: >25 mg/ml
Ethanol: >30 mg/mlPBS (pH 7.2): >1.4 mg/ml | | pka | 4.75±0.10(Predicted) |
| | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2 Usage And Synthesis |
| Uses | bicyclo-PGE2 (bicyclo-PGEM) is a stable decomposition product of PGE2 and 13, 14-dihydro-15-ketone PGE2[1]. | | Definition | ChEBI: Bicyclo-PGE2 is a prostanoid. | | References | [1] Mucha I, et al. Separation of 125I-labelled prostanoid derivatives by reversed-phase high-performance liquid chromatography. J Chromatogr. 1989 Dec 8;483:419-26. DOI:10.1016/s0021-9673(01)93144-9
[2] M. HAMBERG B S. On the Metabolism of Prostaglandins E1 and E2 in Man[J]. Journal of Biological Chemistry, 1971, 246 1: 6713-6721. DOI: 10.1016/s0021-9258(19)45905-x
[3] A LEONHARDT. In vivo formation of prostaglandin E1 and prostaglandin E2 in atopic dermatitis.[J]. British Journal of Dermatology, 1997, 136 3: 337-340.
[4] R C MURPHY G A F. Current approaches to estimation of eicosanoid formation in vivo.[J]. Advances in prostaglandin, thromboxane, and leukotriene research, 1994, 22: 341-348.
[5] E. GRANSTRÖM . Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability[J]. Prostaglandins, 1980, 19 6: Pages 933-957. DOI: 10.1016/0090-6980(80)90127-6 |
| | 11-DEOXY-13,14-DIHYDRO-15-KETO-11BETA,16CHI-CYCLOPROSTAGLANDIN E2 Preparation Products And Raw materials |
|